SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Arterial Remodeling Technologies (“ART”) Reports $2.9 Million Cash Infusion to Prepare Its Next-generation Bioresorbable Stent for First-in-Human Study